Tech Company Financing Transactions
Disc Medicine Funding Round
Disc Medicine closed a $62.50 funding round on 2/14/2023. Backers included Bain Capital Life Sciences, Access Biotechnology and OrbiMed.
Transaction Overview
Company Name
Announced On
2/14/2023
Transaction Type
Venture Equity
Amount
$62
Round
Undisclosed
Investors
Proceeds Purpose
Disc Medicine, Inc. a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Cambridgepark Dr. 103
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Undisclosed
Website
Email Address
Overview
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis). Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic disease.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 2/14/2023: Aspire venture capital transaction
Next: 2/14/2023: Suite Studios venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs